TWI334867B - Therapeutic compounds - Google Patents

Therapeutic compounds Download PDF

Info

Publication number
TWI334867B
TWI334867B TW096124262A TW96124262A TWI334867B TW I334867 B TWI334867 B TW I334867B TW 096124262 A TW096124262 A TW 096124262A TW 96124262 A TW96124262 A TW 96124262A TW I334867 B TWI334867 B TW I334867B
Authority
TW
Taiwan
Prior art keywords
group
cr9r10
compound
independently selected
aryl
Prior art date
Application number
TW096124262A
Other languages
English (en)
Chinese (zh)
Other versions
TW200811159A (en
Inventor
Simon Paul Planken
Scott Channing Sutton
Rongliang Chen
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TW200811159A publication Critical patent/TW200811159A/zh
Application granted granted Critical
Publication of TWI334867B publication Critical patent/TWI334867B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW096124262A 2006-07-05 2007-07-04 Therapeutic compounds TWI334867B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80659606P 2006-07-05 2006-07-05
US91098807P 2007-04-10 2007-04-10
US94180807P 2007-06-04 2007-06-04

Publications (2)

Publication Number Publication Date
TW200811159A TW200811159A (en) 2008-03-01
TWI334867B true TWI334867B (en) 2010-12-21

Family

ID=38515807

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096124262A TWI334867B (en) 2006-07-05 2007-07-04 Therapeutic compounds

Country Status (24)

Country Link
US (1) US7919488B2 (sr)
EP (1) EP2046774A1 (sr)
KR (1) KR20090034958A (sr)
CN (1) CN101511812A (sr)
AP (1) AP2009004763A0 (sr)
AR (1) AR062154A1 (sr)
AU (1) AU2007270814B2 (sr)
CA (1) CA2660031A1 (sr)
CO (1) CO6150178A2 (sr)
CR (1) CR10573A (sr)
EA (1) EA200900135A1 (sr)
GT (1) GT200700053A (sr)
IL (1) IL196490A0 (sr)
MA (1) MA30629B1 (sr)
MX (1) MX2009000482A (sr)
NO (1) NO20090346L (sr)
NZ (1) NZ574207A (sr)
PE (1) PE20080998A1 (sr)
RS (1) RS20090036A (sr)
TN (1) TN2009000033A1 (sr)
TW (1) TWI334867B (sr)
UY (1) UY30460A1 (sr)
WO (1) WO2008004096A1 (sr)
ZA (1) ZA200900478B (sr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009005252A (es) * 2006-11-17 2009-05-28 Abbott Lab Aminopirrolidinas como antagonistas del receptor de quimiocina.
JP2010521456A (ja) * 2007-03-13 2010-06-24 アレテ セラピューティクス, インコーポレイテッド 可溶性エポキシドヒドロラーゼ阻害剤
EP2257536A4 (en) 2008-02-14 2011-03-23 Amira Pharmaceuticals Inc CYCLIC DIARYL ETHERS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
US8426449B2 (en) 2008-04-02 2013-04-23 Panmira Pharmaceuticals, Llc Aminoalkylphenyl antagonists of prostaglandin D2 receptors
DE102008057364A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057344A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057343A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041241A1 (de) 2009-09-11 2011-08-04 Bayer Schering Pharma Aktiengesellschaft, 13353 Substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041242A1 (de) 2009-09-11 2011-12-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
US8383654B2 (en) 2008-11-17 2013-02-26 Panmira Pharmaceuticals, Llc Heterocyclic antagonists of prostaglandin D2 receptors
TWI532737B (zh) 2010-06-30 2016-05-11 艾諾屋製藥公司 可溶性鳥苷酸環化酶(sGC)刺激物
JP5878546B2 (ja) 2010-11-09 2016-03-08 アイアンウッド ファーマシューティカルズ インコーポレイテッド sGC刺激剤
CA2861804C (en) 2011-12-27 2021-10-26 Ironwood Pharmaceuticals, Inc. 2-benzyl,3(pyrimidin-2-yl)substituted pyrazoles useful as sgc stimulators
WO2014000178A1 (en) * 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Sulfonamide derivatives and methods of use thereof for improving the pharmacokinetics of a drug
WO2014194519A1 (en) 2013-06-07 2014-12-11 Merck Sharp & Dohme Corp. Imidazole derivatives and methods of use thereof for improving pharmacokinetics of drug
WO2015070366A1 (en) * 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
WO2015070367A1 (en) 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Piperidine or piperazine linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0024795D0 (en) * 2000-10-10 2000-11-22 Hoffmann La Roche Pyrazole derivatives for the treatment of viral diseases
SI1373263T1 (en) * 2001-04-05 2005-04-30 Torrent Pharmaceuticals Ltd Heterocyclic compounds for aging-related and diabetic vascular complications
US7008953B2 (en) * 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7662844B2 (en) * 2004-07-12 2010-02-16 Osi Pharmaceuticals, Inc. Naphthylene derivatives as cytochrome P450 inhibitors
GEP20115230B (en) * 2005-09-23 2011-06-10 Pfizer Prod Inc Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4

Also Published As

Publication number Publication date
MA30629B1 (fr) 2009-08-03
NZ574207A (en) 2010-10-29
IL196490A0 (en) 2011-07-31
KR20090034958A (ko) 2009-04-08
ZA200900478B (en) 2010-04-28
GT200700053A (es) 2009-08-03
US20080021011A1 (en) 2008-01-24
PE20080998A1 (es) 2008-08-15
UY30460A1 (es) 2008-02-29
WO2008004096A1 (en) 2008-01-10
TN2009000033A1 (fr) 2010-08-19
US7919488B2 (en) 2011-04-05
CR10573A (es) 2009-02-12
RS20090036A (sr) 2010-06-30
CA2660031A1 (en) 2008-01-10
TW200811159A (en) 2008-03-01
AU2007270814B2 (en) 2011-07-14
NO20090346L (no) 2009-02-19
MX2009000482A (es) 2009-01-27
EA200900135A1 (ru) 2009-06-30
AR062154A1 (es) 2008-10-22
AP2009004763A0 (en) 2009-02-28
CN101511812A (zh) 2009-08-19
EP2046774A1 (en) 2009-04-15
CO6150178A2 (es) 2010-04-20
AU2007270814A1 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
JP7268116B2 (ja) Rock阻害剤としてのスピロヘプタンサリチルアミドおよび関連性化合物
ES3025032T7 (en) Carboxy-benzimidazole glp-1r modulating compounds
US7919488B2 (en) Therapeutic compounds
CN114787159B (zh) Brm靶向化合物及相关使用方法
ES2866152T3 (es) Derivados de tirosina amida como inhibidores de la Rho-quinasa
JP2023071767A (ja) Brm標的化化合物および関連使用方法
US20240400518A1 (en) Sos1 inhibitor and use thereof
CN105764514B (zh) 作为tam族激酶抑制剂的氨基吡啶衍生物
KR20240127910A (ko) Sos1 억제제 및 항암제를 포함하는 암 치료용 약학 조성물
AU2012284540B2 (en) TRPV4 antagonists
TW202128699A (zh) 治療性化合物
JP2017505337A (ja) Irak4阻害剤としてのインダゾール化合物
CN105339368A (zh) 3-芳基-取代的咪唑并[1,2-a]吡啶及其用途
AU2017262960B2 (en) Substituted 5,6,7,8-tetrahydro(1,2,4)triazolo(4,3-a)pyridine-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo(2,1-c)(1,2,4)triazol-3-ones, and use thereof
CN109803968A (zh) 吡啶并嘧啶酮cdk2/4/6抑制剂
TW202031661A (zh) 對抗b型肝炎病毒(hbv)之新穎6,7-二氫-4h-吡唑并[1,5-a]吡吲哚-2-甲醯胺活性劑
TW201111380A (en) Heterocyclic urea derivatives and methods of use thereof
WO2024097953A1 (en) Naphthyridine compounds for inhibition of raf kinases
ES3041596T3 (en) Dihydrofuropyridine derivatives as rho- kinase inhibitors
JP7618898B1 (ja) ヒト呼吸器合胞体ウイルス及びメタニューモウイルスの阻害薬
AU2018293752A1 (en) Heterocyclylmethylidene derivatives and their use as modulators of mGluR5 receptors
ES2987656T3 (es) 5,6,7,8-tetrahidro[1,2,4]triazolo[4,3-a]piridin-3(2H)-onas y 2,5,6,7-tetrahidro-3h-pirrolo[2,1-c][1,2,4]triazol-3-onas sustituidas y uso de las mismas
HK40072725A (en) Therapeutic compounds
HK1137173A (en) Pyrazole derivatives as cytochrome p450 inhibitors
AU2015215863A1 (en) Inhibitors of jun n-terminal kinase

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees